{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=8&q=venetoclax", "query": { "intervention": "venetoclax", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 465, "total_pages": 47, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=9&q=venetoclax&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=7&q=venetoclax&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T01:37:37.197Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04872790", "title": "Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B Acute Lymphoblastic Leukemia", "B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1", "Mixed Phenotype Acute Leukemia", "Recurrent B Acute Lymphoblastic Leukemia", "Recurrent Mixed Phenotype Acute Leukemia" ], "interventions": [ { "name": "Dasatinib", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Blinatumomab", "type": "BIOLOGICAL" }, { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2022-09-02", "completion_date": "2027-12-02", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-23T01:37:37.197Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04872790" }, { "nct_id": "NCT01889186", "title": "A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "17p Deletion", "Cancer of the Blood and Bone Marrow" ], "interventions": [ { "name": "ABT-199 (Main Cohort)", "type": "DRUG" }, { "name": "ABT-199 (Safety Expansion Cohort)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 158, "start_date": "2013-06-27", "completion_date": "2020-12-15", "has_results": true, "last_update_posted_date": "2021-12-16", "last_synced_at": "2026-10-23T01:37:37.197Z", "location_count": 16, "location_summary": "Tucson, Arizona • Duarte, California • La Jolla, California + 11 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01889186" }, { "nct_id": "NCT07511062", "title": "Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "TP53 Gene Mutation" ], "interventions": [ { "name": "Decitabine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Axatilimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northside Hospital, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2027-01-31", "completion_date": "2030-08-01", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-23T01:37:37.197Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07511062" }, { "nct_id": "NCT06708897", "title": "A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "CLL / SLL", "CLL (Chronic Lymphocytic Leukemia)", "SLL (Small Lymphocytic Lymphoma)", "Marginal Zone Lymphoma(MZL)", "Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia" ], "interventions": [ { "name": "Lonitoclax (ZE50-0134)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lomond Therapeutics Holdings, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2025-04-08", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-23T01:37:37.197Z", "location_count": 5, "location_summary": "Louisville, Kentucky • Chapel Hill, North Carolina • Cincinnati, Ohio + 2 more", "locations": [ { "city": "Louisville", "state": "Kentucky" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06708897" }, { "nct_id": "NCT04905810", "title": "Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Recurrent Acute Myeloid Leukemia" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brian Jonas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2022-02-09", "completion_date": "2025-12-01", "has_results": false, "last_update_posted_date": "2024-05-29", "last_synced_at": "2026-10-23T01:37:37.197Z", "location_count": 4, "location_summary": "Clovis, California • Los Angeles, California • Sacramento, California + 1 more", "locations": [ { "city": "Clovis", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT04905810" }, { "nct_id": "NCT06644183", "title": "Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia", "Relapsed Leukemia", "Chronic Lymphocytic Leukemia", "Relapsed Cancer", "Refractory Leukemia" ], "interventions": [ { "name": "Roginolisib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jennifer R. Brown, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2025-03-19", "completion_date": "2032-10-01", "has_results": false, "last_update_posted_date": "2026-02-11", "last_synced_at": "2026-10-23T01:37:37.197Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06644183" }, { "nct_id": "NCT01969682", "title": "A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "ABT-199", "type": "DRUG" }, { "name": "Rifampin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2014-04", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2014-05-26", "last_synced_at": "2026-10-23T01:37:37.197Z", "location_count": 1, "location_summary": "Hackensack, New Jersey", "locations": [ { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01969682" }, { "nct_id": "NCT05734495", "title": "Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "Pirtobrutinib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2023-05-02", "completion_date": "2033-01-25", "has_results": false, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-10-23T01:37:37.197Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05734495" }, { "nct_id": "NCT03406156", "title": "A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia (CLL)", "Small Lymphocytic Lymphoma (SLL)" ], "interventions": [ { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 120, "start_date": "2018-08-10", "completion_date": "2023-07-12", "has_results": true, "last_update_posted_date": "2024-08-06", "last_synced_at": "2026-10-23T01:37:37.197Z", "location_count": 15, "location_summary": "Tempe, Arizona • Denver, Colorado • Kansas City, Missouri + 12 more", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Eugene", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03406156" }, { "nct_id": "NCT07024706", "title": "Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia (CLL)", "Small Lymphocytic Lymphoma (SLL)" ], "interventions": [ { "name": "Acalabrutinib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 80, "start_date": "2026-06-04", "completion_date": "2033-03-23", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-10-23T01:37:37.197Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Charlotte, North Carolina • Durham, North Carolina + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07024706" } ] }